6533b852fe1ef96bd12ab560
RESEARCH PRODUCT
Combined treatment with bexarotene and rosuvastatin reduces angiotensin-II-induced abdominal aortic aneurysm in apoE−/−mice and angiogenesis
María José SanzLaura PiquerasM JuezA. NavarroP. EscuderoHerminia González-navarroE FurioC Ferrandosubject
PharmacologyBexaroteneAngiogenesisPharmacologyRetinoid X receptorBiologymedicine.diseaseenvironment and public healthAngiotensin IINeovascularizationAortic aneurysmRosuvastatin Calciumcardiovascular systemmedicinelipids (amino acids peptides and proteins)Rosuvastatincardiovascular diseasesmedicine.symptommedicine.drugdescription
Background and Purpose Abdominal aortic aneurysm (AAA) is a degenerative vascular disease associated with angiogenesis. Bexarotene is a retinoid X receptor (RXR) ligand with anti-angiogenic activity. Statins also exert anti-angiogenic activity and activate PPARs. Because RXR ligands form permissive heterodimers with PPARs and a single anti-angiogenic drug may not be sufficient to combat the wide array of angiogenic factors produced during AAA, we evaluated the effect of combined low doses of bexarotene and rosuvastatin in a mouse model of AAA.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-03-26 | British Journal of Pharmacology |